Search results for "Glycemic efficacy"

showing 2 items of 2 documents

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary…

Malemedicine.medical_specialtyUrologyKaplan-Meier EstimateType 2 diabetesPharmacologyWeight GainRosiglitazoneGlibenclamidechemistry.chemical_compoundDouble-Blind MethodDiabetes mellitusGlyburidemedicineHumansHypoglycemic AgentsProportional Hazards ModelsGlycemicGlycated HemoglobinGlycemic efficacyWaist-Hip Ratiobusiness.industryCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomeDiabetes Mellitus Type 2chemistryCardiovascular DiseasesFemaleThiazolidinedionesGlycated hemoglobinbusinessRosiglitazonemedicine.drugNew England Journal of Medicine
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct